Sanofi to present growth opportunities and development strategy for Dupixent® (dupilumab) in type 2 inflammatory diseases

NEXT STORY
LIDDS announces a capital raise of a total of approximately SEK 59.3 million and accordingly secures long-term financing
PREV STORY
Sorrento Announces It Has Submitted an Emergency Use Authorization (EUA) Application for the COVI-TRACK Diagnostic Test for the Detection of Antibodies to SARS-CoV-2
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

OncoMed Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting

author_avatar
NASDAQ Market News

Biocartis’ Idylla(TM) Instrument and Idylla(TM) Console exempt from US FDA 510(k) notification requirements

Biocartis Group NV ('Biocartis' or the 'Company'), an innovative molecular diagnostics company (Euronext Brussels: ...

author_avatar
NASDAQ Market News

Humacyte Leadership to Present at Five Scientific Events in September

author_avatar
NASDAQ Market News